Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/5/2025

Non-Cirrhotic Portal Hypertension Management

Diagnostic Approach

  • The European Association for the Study of the Liver recommends diagnosing non-cirrhotic portal hypertension (NCPH) by systematically excluding cirrhosis and identifying the specific vascular lesion causing portal hypertension 1, 2
  • Liver biopsy is the gold standard for excluding cirrhosis and identifying characteristic histologic features in idiopathic non-cirrhotic portal hypertension (INCPH) 1, 2, 3
  • All other causes of non-cirrhotic portal hypertension, including extrahepatic portal vein obstruction (EHPVO), Budd-Chiari syndrome, schistosomiasis, and other vascular disorders, should be excluded before labeling as INCPH 1, 2
  • Portal vein patency should be assessed with imaging, screening for portal vein thrombosis (PVT) at baseline and then at least every 6 months 1, 2, 3, 4

Management of Variceal Bleeding

  • The American Association for the Study of Liver Diseases recommends managing portal hypertension complications in NCPH patients using the same approach as for cirrhotic portal hypertension, with endoscopic band ligation as first-line therapy for acute variceal bleeding 1, 2, 3
  • Endoscopic band ligation (EBL) is preferred over sclerotherapy for acute variceal bleeding in INCPH patients, based on data from cirrhosis and EHPVO 1, 2, 3, 4
  • TIPS placement should be considered for uncontrolled bleeding when endoscopic therapy fails, as it is technically feasible and effective in NCPH with lower risk of hepatic encephalopathy due to preserved liver function 1, 5, 2, 3, 4
  • Non-selective beta-blockers (NSBBs) should be initiated for prevention of rebleeding, reducing portal pressure by decreasing cardiac output and causing splanchnic vasoconstriction 1, 2, 3, 6, 4
  • A target reduction of 10-12% in hepatic venous pressure gradient (HVPG) or reduction to <12 mmHg is recommended to protect against variceal bleeding 6, 4

Management of Portal Vein Thrombosis

  • The European Association for the Study of the Liver recommends screening for PVT every 6 months and considering anticoagulation selectively based on thrombotic risk factors 1, 2, 3, 4
  • Anticoagulation should be reserved for patients with clear prothrombotic conditions or those who develop acute PVT 1, 2, 3, 4
  • Early anticoagulation can achieve recanalization in 54% of PVT cases when initiated promptly 4
  • TIPS should be considered for extensive PVT with bowel ischemia, as it is technically feasible and effective in reducing portal hypertension even with extensive thrombosis 5

Management of Portal Hypertensive Gastropathy

  • The American Association for the Study of Liver Diseases recommends treating bleeding from portal hypertensive gastropathy with portal pressure-lowering strategies rather than hemostatic correction 7, 8
  • Vasoactive therapy (NSBBs) should be used acutely for active bleeding from portal hypertensive gastropathy, and maintained chronically for long-term management 7, 8
  • TIPS should be considered for refractory bleeding from portal hypertensive gastropathy when medical therapy fails 7, 8

Advanced Interventions

  • TIPS demonstrates similar technical success and clinical outcomes in INCPH compared to cirrhotic portal hypertension, with lower encephalopathy risk 5, 4
  • TIPS controls ascites with 5-year survival of 60-89% in NCPH patients, and hepatic encephalopathy rates may exceed 35% after TIPS even in NCPH 4, 1, 5, 2, 4
  • TIPS surveillance is mandatory, with imaging performed at 1-6 months post-TIPS initially, then every 6-12 months to detect stenosis/occlusion 5
  • Liver transplantation should be considered for unmanageable portal hypertension complications or progressive liver failure, although indications are limited in INCPH since liver function is typically preserved 1, 2, 3, 4